Drugs by condition
Drugs approved for pulmonary arterial hypertension
Last checked: Nov 20, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations
Brand-name drugs approved
19
Still marketed, NDA or BLA
Drug classes
6
Novel drugs
7
New molecular entities and new biologics
In development
11
Investigational drugs in Phase 2 or 3
Newest approvals
The most recently first-approved brand-name drugs for pulmonary arterial hypertension.
- Yutrepia (Treprostinil Sodium) · Liquidia Tech May 23, 2025
- Winrevair (Sotatercept-Csrk) · Merck Sharp Dohme NovelBreakthrough therapyPriority reviewOrphanMar 26, 2024
- Opsynvi (Macitentan, Tadalafil) · Actelion OrphanMar 22, 2024
- Tadliq (Tadalafil) · Cmp Dev LLC Jun 17, 2022
- Tyvaso Dpi (Treprostinil) · United Therap Priority reviewOrphanMay 23, 2022
All approved drugs for pulmonary arterial hypertension, by class
Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 66 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.
Prostacycline Vasodilator (5)
- Remodulin Treprostinil · United Therap · 2002
- Tyvaso Dpi Treprostinil · United Therap · 2022
- Orenitram Treprostinil Diolamine · United Therap · 2013
- Tyvaso Treprostinil · United Therap · 2009
- Veletri Epoprostenol Sodium · Actelion · 2008
Phosphodiesterase 5 Inhibitor (3)
Prostacyclin Receptor Agonist (2)
Endothelin Receptor Antagonist (2)
Soluble Guanylate Cyclase Stimulator (1)
- Adempas Riociguat · Bayer Hlthcare · 2013
Class not listed in FDA's data (6)
Drugs in development for pulmonary arterial hypertension
Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.
- INS1009Treprostinil PalmitilPhase 37 trials
Insmed Incorporated · Interstitial Lung Disease, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- IKT-001Phase 32 trials
Inhibikase Therapeutics · Pulmonary Arterial Hypertension, Pulmonary Arterial Hypertension (PAH)
- RalinepagAPD811Phase 32 trials
United Therapeutics · PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension
- SeralutinibPhase 32 trials
Gossamer Bio USA, Inc. · Pulmonary Arterial Hypertension
- HS235Phase 22 trials
35Pharma Inc., a GSK company · Pulmonary Arterial Hypertension, Pulmonary Hypertension, Heart Failure With Preserved Ejection Fraction
- NS-863Phase 22 trials
NS Pharma, Inc. · Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD), Pulmonary Arterial Hypertension
- APL-9796Phase 21 trial
Apollo Therapeutics Ltd · Pulmonary Arterial Hypertension
- DIAG723Phase 21 trial
Diagonal Therapeutics, Inc. · Hereditary Hemorrhagic Telangiectasia, Pulmonary Arterial Hypertension
- PF-07868489Phase 21 trial
Pfizer · Pulmonary Arterial Hypertension
- REGN13335Phase 21 trial
Regeneron · Pulmonary Arterial Hypertension (PAH)
- ROC-101Phase 21 trial
AllRock Bio, Inc. · Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
1 discontinued brand-name drugs whose label still names it
- Revatio Sildenafil Citrate
More on pulmonary arterial hypertension: recruiting trials · published research
Related in respiratory: Asthma · COPD · Cystic fibrosis · Idiopathic pulmonary fibrosis · Allergies (allergic rhinitis)
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.